Summary of Key Outcomes

Warning: The NCBI web site requires JavaScript to function. more...

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Pharmacoeconomic Review Report: Obeticholic Acid (Ocaliva): (Intercept Pharma Canada, Inc.): Indication: For the treatment of primary biliary cholangitis [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Aug.

Cover of Pharmacoeconomic Review Report: Obeticholic Acid (Ocaliva)

Pharmacoeconomic Review Report: Obeticholic Acid (Ocaliva): (Intercept Pharma Canada, Inc.): Indication: For the treatment of primary biliary cholangitis [Internet].

Show details

Contents

< Prev Next >

Appendix 2Summary of Key Outcomes

Table 7When considering only costs, outcomes, and quality of life, how attractiveis OCA plus UDCA relative to UDCA alone (CDR reanalyses)?

OCA + UDCA vs. UDCA Alone	Attractive	Unattractive
Costs (total)		X
Drug treatment costs alone		X
Clinical outcomes	X
Quality of life	X
Incremental CE ratio or net benefit calculation	$153,155 to $218,310 per QALY

: CDR = CADTH Common Drug Review; CE = cost-effectiveness; OCA = obeticholic acid; UDCA = ursodeoxycholic acid; vs. = versus.
: Source: Manufacturer’s pharmacoeconomic submission.¹

Table 8When considering only costs, outcomes, and quality of life, how attractive is OCA relative to no treatment in UDCA-intolerant patients (CDR reanalyses)?

OCA vs. No Treatment	Attractive	Unattractive
Costs (total)		X
Drug treatment costs alone		X
Clinical outcomes	X
Quality of life	X
Incremental CE ratio or net benefit calculation	$118,341 to $138,666 per QALY

: CDR = CADTH Common Drug Review; CE = cost-effectiveness; OCA = obeticholic acid; UDCA = ursodeoxycholic acid; vs. = versus.
: Source: Manufacturer’s pharmacoeconomic submission.¹

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

Bookshelf ID: NBK534954

Contents

< Prev Next >

PubReader
Print View
Cite this Page
Pharmacoeconomic Review Report: Obeticholic Acid (Ocaliva): (Intercept Pharma Canada, Inc.): Indication: For the treatment of primary biliary cholangitis [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Aug. Appendix 2, Summary of Key Outcomes.
PDF version of this title (1016K)